Daily Sepsis Research Analysis
Analyzed 45 papers and selected 3 impactful papers.
Summary
Three impactful studies span prevention, precision medicine, and supportive care in sepsis. A 37-year nationwide Dutch surveillance links rising infant Group B Streptococcus sepsis to CC17 lineage dominance and shows near-complete projected coverage by maternal vaccines. A multicenter pediatric cohort identifies a PPARγ variant (rs10865710) that magnifies corticosteroid-associated mortality risk in septic shock, while a meta-analysis in burn patients associates adequate vitamin D status with fewer sepsis events and shorter stays.
Research Themes
- Neonatal sepsis epidemiology and vaccine-preventable burden
- Pharmacogenomics and corticosteroid response in pediatric septic shock
- Nutritional and endocrine modulation of sepsis outcomes in critical illness
Selected Articles
1. Group B streptococcal disease in infants 0-3 months in The Netherlands, 1987-2023: a nationwide genomic and epidemiological surveillance study.
Over 37 years of nationwide surveillance in the Netherlands, infant GBS disease incidence rose, driven by sepsis cases and dominance of serotype III/CC17 lineages. Genomic typing showed expanding CC17 proportions, and maternal vaccines (GBS6, GBS‑AlpN) are projected to cover >96% of strains.
Impact: This study quantifies the growing, vaccine-preventable burden of neonatal GBS sepsis with integrated genomics, directly informing maternal immunization policy.
Clinical Implications: Supports accelerated evaluation and deployment of maternal GBS vaccines, prioritization of CC17 surveillance, and reinforcement of early recognition/treatment pathways for neonatal sepsis.
Key Findings
- Incidence increased from 0.19 (1987) to 0.57 (2023) per 1000 live births (p<0.0001), mainly due to sepsis.
- Serotype III accounted for 61% and CC17 for 41% of typed isolates; CC17 rose from 29% to 49% across decades.
- Projected vaccine coverage: 97% by GBS6 and 99% by GBS‑AlpN.
Methodological Strengths
- Nationwide, long-term surveillance with large sample size (n=2212).
- Integration of serotyping, WGS/MLST, and vaccine coverage modeling.
Limitations
- Observational design limits causal inference about drivers of incidence.
- Incomplete genomic data for all isolates (MLST available for 78%).
Future Directions: Evaluate real-world effectiveness and equity impact of maternal GBS vaccination; monitor post-vaccine clonal shifts (especially CC17) and antimicrobial resistance.
BACKGROUND: Group B METHODS: This nationwide observational study identified infants aged 0-89 days with GBS culture-positive sepsis or meningitis between July 1987 and June 2024, through Dutch surveillance. Serotype was determined by latex agglutination. Whole-genome sequencing determined the clonal complex (CC) using multi-locus sequence typing (MLST) and identified virulence factors associated with meningitis. Strain coverage by the maternal vaccines GBS6 and GBS-AlpN were analysed. FINDINGS: 2212 episodes were identified; 1307 (59%) early onset disease (0-6 days) and 905 (41%) late onset disease (7-89 days). Mean annual incidence was 0·33 per 1000 live births and significantly increased from 0·19 in 1987 to 0·57 in 2023 due to an increase in sepsis cases (p < 0·0001). Serotype data was available for 2163 (98%) of 2212 isolates, of which serotype III was most common (1316/2163; 61%), followed by Ia (383/2163; 18%) and II (123/2163; 6%). MLST data was available for 1723 (78%) isolates; CC17 was most common (705/1723; 41%). CC17 increased from 29% (90/308) in 1987-1996 to 49% (262/538) in 2014-2023 (p < 0·0001). 97% (2095/2163) of cases would be covered by the GBS6 vaccine, and 99% (1709/1723) by GBS-AlpN. INTERPRETATION: GBS disease is still increasing in the Netherlands. The GBS6 and GBS-AlpN vaccines would potentially prevent >96% of cases. FUNDING: Netherlands Organisation for Health Research and Development (ZonMW) and ItsME foundation.
2. PPARγ Variant rs10865710 and Mortality in Pediatric Septic Shock Stratified by Corticosteroid Exposure.
In a multicenter pediatric septic shock cohort (n=381), the PPARγ rs10865710 variant was linked to higher 28-day mortality, predominantly among corticosteroid-treated patients (adjusted OR 5.85; HR 5.33). No effect was seen for rs1801282; exploratory eQTL data suggested altered glucocorticoid signaling.
Impact: Identifies a pharmacogenomic interaction with corticosteroids that could guide precision therapy in pediatric septic shock.
Clinical Implications: Corticosteroid use in pediatric septic shock may warrant genetic risk stratification; routine use should be re-evaluated pending validation. Steroid-sparing strategies or alternative immunomodulation may be prioritized in high-risk genotypes.
Key Findings
- rs10865710 carriage increased 28-day mortality (10.2% vs 3.5%; p=0.009).
- Association concentrated in corticosteroid-treated patients (adjusted OR 5.85; HR 5.33).
- No association for rs1801282; eQTL showed trend toward lower NR3C1 expression (p=0.07).
Methodological Strengths
- Multicenter prospective cohort with stratified and adjusted time-to-event analyses.
- Integrated genotyping with RNA-seq eQTL exploration.
Limitations
- Observational design limits causal inference; genotype-guided therapy not tested.
- eQTL subset was small (n=81), requiring replication and mechanistic validation.
Future Directions: Prospective validation in independent cohorts; randomized trials testing steroid strategies stratified by rs10865710; mechanistic studies of glucocorticoid receptor signaling.
OBJECTIVES: To determine whether genetic variation in peroxisome proliferator-activated receptor gamma (PPARγ) is associated with mortality across corticosteroid exposure strata in pediatric septic shock. DESIGN: Multicenter prospective observational study. SETTING: PICUs at multiple U.S. hospitals. PATIENTS: Children 1 week to 10 years old meeting consensus criteria for septic shock. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Genomic DNA was genotyped for two PPARγ single nucleotide variants (SNVs; rs10865710 and rs1801282) using TaqMan assays. Associations with 28-day mortality were evaluated using multivariable logistic regression and Cox proportional hazards models, with analyses stratified by systemic corticosteroid exposure within 72 hours. In a subset with whole-blood RNA sequencing, expression quantitative trait locus (eQTL) analyses assessed genotype effects on candidate transcripts. Among 381 patients, both SNVs were in Hardy-Weinberg equilibrium. Carriage of the rs10865710 mutant allele was associated with higher 28-day mortality (10.2% vs. 3.5%; p = 0.009), whereas rs1801282 showed no association. In stratified analyses, rs10865710 carriage was associated with increased mortality among corticosteroid-treated patients (adjusted odds ratio, 5.85; 95% CI, 1.62-30.44; p = 0.015) but not corticosteroid-naive patients. Similarly, in stratified Cox models, rs10865710 carriage was associated with increased hazard of death among corticosteroid-treated patients (hazard ratio, 5.33; 95% CI, 1.43-19.83; p = 0.013). Genotype was not associated with established mortality risk strata or transcriptomic endotype. In eQTL analyses (n = 81), rs10865710 carriage was not associated with PPARγ expression; however, a trend toward lower glucocorticoid receptor (NR3C1) expression was noted (p = 0.07). CONCLUSIONS: The intronic PPARγ variant rs10865710 is associated with increased mortality in pediatric septic shock, with the association most apparent among corticosteroid-treated patients. Although no cis-eQTL effect on PPARγ expression was detected, exploratory data suggest potential differences in glucocorticoid receptor signaling. Prospective validation and mechanistic studies are warranted.
3. Impact of Vitamin D Levels on Clinical Outcomes in Hospitalized Burn Patients: A Systematic Review and Meta-Analysis.
Across randomized and non-randomized studies, adequate vitamin D status or supplementation in burn patients was associated with shorter total and ICU length of stay and lower rates of sepsis and intubation, without a clear mortality benefit.
Impact: Synthesizes evidence linking vitamin D status to infection risk and resource use in a high-risk surgical ICU population, highlighting a modifiable factor with potential relevance to sepsis prevention.
Clinical Implications: Consider routine assessment and correction of vitamin D deficiency in burn care pathways to potentially reduce sepsis and ventilation needs; definitive mortality effects require larger RCTs.
Key Findings
- Vitamin D sufficiency/supplementation reduced overall hospital and burn ICU length of stay.
- Sepsis and intubation were more frequent in vitamin D–deficient or non-supplemented patients.
- No statistically significant difference in mortality was observed.
Methodological Strengths
- Systematic review and meta-analysis with predefined outcomes and subgroup analyses.
- Multi-database search capturing randomized and non-randomized evidence.
Limitations
- Heterogeneity across studies and inclusion of non-randomized designs may bias estimates.
- Incomplete reporting of dosing, timing, and baseline 25(OH)D levels limits clinical translation.
Future Directions: Large, well-controlled RCTs to define optimal dosing/timing and to test effects on sepsis, ventilation, and survival; mechanistic studies on vitamin D–mediated host defense in burns.
<b>Introduction:</b> Vitamin D plays a key role in immune regulation, inflammation control, and musculoskeletal health. Patients with burn injuries are particularly vulnerable to its deficiency. Despite its importance, current clinical guidelines do not provide a clear consensus on how vitamin D should be managed in this population. <br><br><b>Aim:</b> This meta-analysis aimed to assess the clinical impact of adequate vitamin D levels or supplementation compared to vitamin D deficiency or no supplementation in patients with burns. <br><br><b>Materials and methods:</b> A systematic literature search was conducted in PubMed, Scopus, and Web of Science databases for studies reporting clinical outcomes in these 2 patient groups. The primary outcomes included duration of hospitalization, length of stay in burn intensive care units, mortality, and the incidence of sepsis and intubation. Subgroup analyses were performed for randomized and non-randomized studies. Statistical analysis was conducted using Cochrane's Review Manager. <br><br><b>Results:</b> Patients with sufficient vitamin D levels or those who received supplementation had significantly shorter overall hospitalization and burn intensive care unit stays. Although the difference in mortality was not statistically significant, intubation and sepsis occurred more frequently in patients with vitamin D deficiency or no supplementation. Subgroup analyses confirmed that both randomized and non-randomized studies showed a significantly reduced hospital stay in patients with adequate vitamin D status. <br><br><b>Discussion:</b> The findings suggest that vitamin D management may improve clinical outcomes in burn patients and should be considered in future guidelines. <br><br><b>Conclusions:</b> Further prospective studies with larger patient populations are necessary to establish standardized treatment protocols.